TA-CIN
- Generic Name
- TA-CIN
- Drug Type
- Biotech
- Background
TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
- Indication
Investigated for use/treatment in cervical dysplasia/cancer.
TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers
- Conditions
- Recurrent Human Papillomavirus Type 16 Associated Cancer
- Interventions
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Women & Infants Center, University of Alabama at Birmingham, Birmingham, Alabama, United States
Study of Treatment for HPV16+ ASC-US or LSIL
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 30
- Registration Number
- NCT03913117
- Locations
- 🇺🇸
UAB | The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
- Conditions
- HPV16 Associated Cervical Cancer
- Interventions
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2025-03-04
- Target Recruit Count
- 14
- Registration Number
- NCT02405221
- Locations
- 🇺🇸
Women & Infants Center, University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.